Tempus AI reposted this
👩⚕️ 2000+ connected healthcare providers. 🔬 7.7M+ de-identified records for research. 🤖 60 AI algorithms deployed clinically. ⬇️ It’s why Tempus AI is leading the way in data-driven precision medicine. #NasdaqListed
Skip to main content
Tempus AI reposted this
👩⚕️ 2000+ connected healthcare providers. 🔬 7.7M+ de-identified records for research. 🤖 60 AI algorithms deployed clinically. ⬇️ It’s why Tempus AI is leading the way in data-driven precision medicine. #NasdaqListed
To view or add a comment, sign in
Tempus One continues to evolve, providing enhanced features and cutting-edge technology to support your clinical needs. Features to streamline your workflow include rapid filtering and the ability to order specimen collection kits inside of One. Explore Tempus One here: https://tempus.co/4cqQNJv
To view or add a comment, sign in
A new Next program is now available, focused on the identification of care gaps associated with HER2 testing recommended under clinical guidelines for patients with select metastatic cancers. We’re able to support physicians in closing this specific care gap with an algorithm that runs as part of xR, our RNA sequencing assay, to help surface patients who are particularly likely to benefit from on-guideline IHC testing. Learn more: https://tempus.co/4c55P7f
To view or add a comment, sign in
We now have over one million records with matched clinical and genomic data. This dataset is unique to Tempus and allows us to support the critical research and development of the next generation of cancer treatments. Explore our data offerings: https://tempus.co/3Sr1413
To view or add a comment, sign in
July is Minority Mental Health Month, a time to recognize and address the unique mental health challenges faced by minority communities. This month serves as a reminder to celebrate diversity, and advocate for equitable mental health care. Explore our offerings to bring personalized medicine to mental health: https://tempus.co/3zSxZoC
To view or add a comment, sign in
A recent case study highlights the implementation of Tempus Next at St. Francis Hospital and Heart Center to identify patients with severe Aortic Stenosis (AS) who had not previously been receiving guideline-recommended care. Tempus Next uses AI, including natural language processing, to contextualize patients in real-time using precise patient screening parameters to identify potentially undertreated or untreated patients. Read on: https://tempus.co/3Yb0gRB
To view or add a comment, sign in
We've created one of the world’s largest libraries of human ex vivo tumor organoids with rich clinical and molecular characterization. We're now offering our biopharma customers an opportunity to screen their pre-clinical candidates against 60 organoids that span 10 different cancer indications, and rapidly generate multimodal data to inform drug development programs. To learn more, click here: https://tempus.co/3WvYKbC
To view or add a comment, sign in
Join us for an upcoming webinar, "Integrating Omics in R&D: A new era of biomedical research,” on July 31 at 11 AM CT. Speakers Nike Beaubier, MD, Calvin Chao, MD, and Dr. M. Sharon Stack, PhD will discuss the transformative role of multi-omics in understanding complex disease mechanism and will dive into the integration of diverse omics data, from NGS to proteomics, in research. Register here: https://tempus.co/3Y8HGcK
To view or add a comment, sign in
We’re excited to announce that our multimodal immune profile score (IPS) algorithmic test is now available for RUO. IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. IPS is a pan-cancer, laboratory developed test that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate an IPS from 0-100 and a classification of either IPS-Low or IPS-High. Learn more: https://tempus.co/3y7ylHp
To view or add a comment, sign in
We’re looking for a Molecular Technologist to join our laboratory team in Chicago. The role will work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory. Learn more and apply here: https://tempus.co/3zKkqru #NowHiring #ChicagoJobs
To view or add a comment, sign in
We’re excited to share that we have reached a major milestone of publishing our 500th publication. In the last eight years, we have invested in rigorous scientific research to validate our diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by our multimodal data library. Learn more: https://tempus.co/462AT68
To view or add a comment, sign in
Director of Operations, Molecular Division at ARUP Laboratories
1moInteresting!